Drugs Made In America Acquisition (DMAAU) Net Cash Flow (2025)

Drugs Made In America Acquisition (DMAAU) reported Net Cash Flow of $5420.0 for Q4 2025, up 5261.9% quarter-over-quarter from -$105.0 in Q3 2025.

Drugs Made In America Acquisition (DMAAU) Net Cash Flow (2025) Analysis & Trends

Drugs Made In America Acquisition has reported Net Cash Flow for 1 years, with the latest figure at $5420.0 in Q4 2025.

For the quarter ending Q4 2025, Net Cash Flow changed N/A year-over-year to $5420.0; the trailing twelve-month figure through Dec 2025 stood at $4786.0 (changed N/A YoY), and the FY2025 full-year result was $4786.0, up 254.26% from the prior year.
Net Cash Flow for Q4 2025 stood at $5420.0, up from -$105.0 in the prior quarter.
The five-year high for Net Cash Flow was $5420.0 in Q4 2025, with the low at -$428.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	EQV Ventures Acquisition	477.69 Mn	477.69 Mn	-	378,972.00
2	Berto Acquisition	312.46 Mn	312.46 Mn	-	-369,667.00
3	Centurion Acquisition	311.65 Mn	311.65 Mn	-	-72,157.00
4	GP-Act III Acquisition	311.36 Mn	311.36 Mn	-	-32,793.00
5	Churchill Capital Corp IX	310.79 Mn	310.79 Mn	-	165,329.00
6	WEN Acquisition	309.15 Mn	309.15 Mn	-	-208,889.00
7	Bold Eagle Acquisition	275.54 Mn	275.54 Mn	-	328,760.00
8	Soulpower Acquisition	264.91 Mn	264.91 Mn	-	-150,705.00
9	BTC Development	262.16 Mn	262.16 Mn	-	-537,350.00
10	Drugs Made In America Acquisition	-	-	-	5,420.00

Download Data